Ascendis Pharma (ASND) Tops Q4 EPS by 37c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR1.54), EUR0.37 better than the analyst estimate of (EUR1.91). Revenue for the quarter came in at EUR137.7 million versus the consensus estimate of EUR85.87 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Sanuwave Q2 2026 revenue tops revised guidance range
• Gold Royalty acquires two Nevada royalties for $0.8 million